Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT04940078
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Søborg, Denmark
🇨🇦Altasciences Company Inc., Montreal, Quebec, Canada
Compassionate Use of Concizumab if You Have Haemophilia
- Conditions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT04921956
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸Southern Specialty Clinic, Flowood, Mississippi, United States
🇺🇸ECU Sickle Cell Comp Clinic, Greenville, North Carolina, United States
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 617
- Registration Number
- NCT04916470
- Locations
- 🇮🇳
Gandhi Memorial Hospital- King George's Medical University, Lucknow, Uttar Pradesh, India
🇮🇳G B Pant Institute of Postgraduate Medical Education and Res, New Delhi, India
🇮🇳Max Super Speciality Hospital_New Delhi, New Delhi, India
Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT04892069
- Locations
- 🇱🇧
Novo Nordisk Investigational Site, Beirut, Hamra, Beirut, Lebanon
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
- Conditions
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 582
- Registration Number
- NCT04880850
- Locations
- 🇺🇸
UT Southwestern Med Cntr, Dallas, Texas, United States
🇯🇵Noritake Clinic, Ushiku-shi, Ibaraki, Japan
🇺🇸Amarillo Med Spec LLP, Amarillo, Texas, United States
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 650
- Registration Number
- NCT04878393
- Locations
- 🇯🇵
Master Centre for Japan, Tokyo, Japan
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men
- Conditions
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT04878406
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Fukuoka, Japan
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
- Conditions
- Interventions
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 105
- Registration Number
- NCT04865770
- Locations
- 🇺🇸
Prolato Clinical Research Cntr, Houston, Texas, United States
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
🇺🇸N America Res Inst - San Dimas, San Dimas, California, United States
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 336
- Registration Number
- NCT04862923
- Locations
- 🇬🇧
Master Centre for United Kingdom, Crawley, United Kingdom
A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT04857398
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China